Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
about
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Evaluation of Prexasertib, a C ...... with Squamous Cell Carcinoma.
@en
Evaluation of Prexasertib, a C ...... with Squamous Cell Carcinoma.
@nl
type
label
Evaluation of Prexasertib, a C ...... with Squamous Cell Carcinoma.
@en
Evaluation of Prexasertib, a C ...... with Squamous Cell Carcinoma.
@nl
prefLabel
Evaluation of Prexasertib, a C ...... with Squamous Cell Carcinoma.
@en
Evaluation of Prexasertib, a C ...... with Squamous Cell Carcinoma.
@nl
P2093
P2860
P1476
Evaluation of Prexasertib, a C ...... with Squamous Cell Carcinoma.
@en
P2093
Aimee Bence Lin
David S Hong
Howard A Burris
Jeffrey Infante
Johanna C Bendell
Kathleen N Moore
Lisa Golden
Manish R Patel
Ricardo Martinez
P2860
P356
10.1158/1078-0432.CCR-17-3347
P407
P577
2018-04-11T00:00:00Z